Compare Bath & Body Works Inc (BBWI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Sana Biotechnology Inc — how do they compare? Bath & Body Works Inc trades at $18.24 (market cap $3.81B), while Sana Biotechnology Inc trades at $3.76 (market cap $1.13B). The key difference: Bath & Body Works Inc is far larger — about 3.4× Sana Biotechnology Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BBWI | SANA | |
|---|---|---|
Market Cap | $3.81B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $5.92 |
52-Week Low | $14.85 | $2.68 |
Enterprise Value | $7.70B | $1.05B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $18.48, down 4.35% today, reflecting bearish technical signals but attractive valuations with a P/E of 5.36 and P/S of 0.54. Recent earnings show mixed results, with Q1 2026 beating estimates, while revenue has declined over five years. The company maintains strong gross margins above 43% and positive cash flow, supported by strategic expansions into Brazil and a partnership with Ulta Beauty announced in June 2026.
The stock presents a value opportunity given low multiples and analyst consensus price target of $22.11, though risks include persistent revenue declines, high debt levels, and negative shareholder equity. Investor sentiment is cautiously optimistic amid turnaround efforts, but technical weakness suggests near-term pressure.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
